All In Biotech

NDA 018657 · Baxter Hlthcare

Flagyl I.V. Rtu In Plastic Container

Metronidazole · Injection · Nitroimidazole Antimicrobial

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Dec 24, 1981

Approved uses

2

Original approval plus efficacy supplements

Registered trials

728

132 Phase 3, 52 recruiting

FAERS reports

48,091

0 serious, 5,412 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.

What it is approved for

From the label in effect Nov 21, 2025.

INDICATIONS AND USAGE Treatment of Anaerobic Bacterial Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibacterial drugs appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. • Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis , B. distasonis , B. ovatus , B. thetaiotaomicron , B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species in adults and pediatric patients less than 4 months of age. • Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults. • Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species and Fusobacterium species in adults. • Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species in adults. • Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group in adults. • Central Nervous System (CNS) Infections , including meningitis...

Mechanism: Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and is activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intra-cellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical. Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 17, 1988 Supplement 7 · Efficacy
  • Dec 24, 1981 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • FLAGYL I.V. RTU IN PLASTIC CONTAINER · METRONIDAZOLE 500MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,655
  • nausea3,458
  • off label use3,383
  • diarrhoea2,713
  • vomiting2,329
  • pyrexia2,288
  • headache2,258
  • abdominal pain2,119
  • pain2,119
  • fatigue1,959
  • dizziness1,684
  • condition aggravated1,634

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004459
2005480
2006482
2007511
2008320
2009676
2010858
20111,164
20121,431
20131,112
20141,451
20152,167
20162,469
20172,507
20184,185
20194,489
20203,817
20213,868
20223,400
20233,458
20243,160
20253,437
20262,187

Recalls

2 FDA enforcement reports for this application.

  • Jan 21, 2016 · Class I · Terminated

    Presence of Particulate Matter: identified as a cloth fiber.

  • May 21, 2013 · Class II · Terminated

    Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred...

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,032 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.